Antibody Response and Safety After mRNA-1273 SARS-CoV-2 Vaccination in Peritoneal Dialysis Patients - the Vienna Cohort.
2019-nCoV Vaccine mRNA-1273
/ administration & dosage
Adult
Aged
Aged, 80 and over
Antibodies, Viral
Antibody Formation
/ immunology
COVID-19
/ immunology
Cohort Studies
Comorbidity
Female
Host-Pathogen Interactions
/ immunology
Humans
Immunocompromised Host
Immunogenicity, Vaccine
Male
Middle Aged
Peritoneal Dialysis
Retrospective Studies
SARS-CoV-2
/ immunology
Vaccination
COVID-19
antibody response
dialysis
mRNA-1273
safety
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2021
2021
Historique:
received:
21
09
2021
accepted:
11
11
2021
entrez:
20
12
2021
pubmed:
21
12
2021
medline:
5
1
2022
Statut:
epublish
Résumé
Dialysis patients are at high risk for a severe clinical course after infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Safety and early immune responses after mRNA-based vaccination have been reported mostly in patients on hemodialysis (HD), whereas reports of peritoneal dialysis (PD) patients remain rare. In this retrospective observational study, 39 PD patients had received two doses of the mRNA-1273 Moderna Four weeks after the first dose of mRNA-1273 vaccine 33 of 39 (84.6%) PD patients seroconverted and presented with 6.62 U/mL (median; IQR 1.57-22.5) anti-SARS-CoV-2 S antibody titers. After the second dose, 38 of 39 (97.4%) PD patients developed anti-SARS-CoV-2 S antibodies and titers increased significantly (median 968 U/mL; IQR 422.5-2500). Pain at the injection site was the most common local adverse event (AE) (71%). Systemic AEs occurring after the first dose were mostly fatigue (33%) and headache (20%). No severe systemic AEs were reported after the first injection. After the second dose the incidence and the severity of the systemic AEs increased. The most common systemic AEs were: fatigue (40.5%), headache (22.5%), joint pain (20%), myalgia (17.5%) and fever (13%). Lower Davies Comorbidity Score (p=0.04) and shorter dialysis vintage (p=0.017) were associated with higher antibody titers after the first dose. Patients with higher antibody titers after the first dose tended to have higher antibody titers after the second dose (p=1.53x10 Peritoneal dialysis patients in this cohort had a high seroconversion rate of 97.4%, showed high antibody titers after full vaccination and tolerated the anti-SARS-CoV-2 mRNA-1273 vaccine well without serious adverse events.
Sections du résumé
Background
Dialysis patients are at high risk for a severe clinical course after infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Safety and early immune responses after mRNA-based vaccination have been reported mostly in patients on hemodialysis (HD), whereas reports of peritoneal dialysis (PD) patients remain rare.
Methods
In this retrospective observational study, 39 PD patients had received two doses of the mRNA-1273 Moderna
Results
Four weeks after the first dose of mRNA-1273 vaccine 33 of 39 (84.6%) PD patients seroconverted and presented with 6.62 U/mL (median; IQR 1.57-22.5) anti-SARS-CoV-2 S antibody titers. After the second dose, 38 of 39 (97.4%) PD patients developed anti-SARS-CoV-2 S antibodies and titers increased significantly (median 968 U/mL; IQR 422.5-2500). Pain at the injection site was the most common local adverse event (AE) (71%). Systemic AEs occurring after the first dose were mostly fatigue (33%) and headache (20%). No severe systemic AEs were reported after the first injection. After the second dose the incidence and the severity of the systemic AEs increased. The most common systemic AEs were: fatigue (40.5%), headache (22.5%), joint pain (20%), myalgia (17.5%) and fever (13%). Lower Davies Comorbidity Score (p=0.04) and shorter dialysis vintage (p=0.017) were associated with higher antibody titers after the first dose. Patients with higher antibody titers after the first dose tended to have higher antibody titers after the second dose (p=1.53x10
Conclusions
Peritoneal dialysis patients in this cohort had a high seroconversion rate of 97.4%, showed high antibody titers after full vaccination and tolerated the anti-SARS-CoV-2 mRNA-1273 vaccine well without serious adverse events.
Identifiants
pubmed: 34925359
doi: 10.3389/fimmu.2021.780594
pmc: PMC8674530
doi:
Substances chimiques
Antibodies, Viral
0
2019-nCoV Vaccine mRNA-1273
EPK39PL4R4
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
780594Informations de copyright
Copyright © 2021 Beilhack, Monteforte, Frommlet, Gaggl, Strassl and Vychytil.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Sci Immunol. 2021 Jun 15;6(60):
pubmed: 34131023
Kidney Int Rep. 2021 Sep;6(9):2292-2304
pubmed: 34250319
JAMA Netw Open. 2021 Sep 1;4(9):e2123622
pubmed: 34473256
Nephrol Dial Transplant. 2021 Apr 11;:
pubmed: 33839785
Nephrol Dial Transplant. 2021 Aug 27;36(9):1704-1709
pubmed: 34057463
Ann Rheum Dis. 2021 Oct;80(10):1330-1338
pubmed: 34127481
Biochem Biophys Res Commun. 2021 Jan 29;538:192-203
pubmed: 33069360
Vaccines (Basel). 2021 Apr 08;9(4):
pubmed: 33918085
Am J Transplant. 2021 Aug;21(8):2719-2726
pubmed: 33866672
Nat Rev Nephrol. 2021 May;17(5):291-293
pubmed: 33558753
Kidney Int. 1984 Jan;25(1):124-8
pubmed: 6233450
Kidney Int. 2021 Aug;100(2):476-477
pubmed: 34081947
Am J Kidney Dis. 1995 Sep;26(3):454-60
pubmed: 7645553
Am J Kidney Dis. 2021 Oct;78(4):571-581
pubmed: 34174364
Kidney Int. 2021 Jun;99(6):1494-1496
pubmed: 33887320
J Am Soc Nephrol. 2021 Oct;32(10):2435-2438
pubmed: 34117129
J Am Soc Nephrol. 2021 Nov;32(11):2735-2742
pubmed: 34348908
CMAJ. 2021 May 31;193(22):E793-E800
pubmed: 33980499
Front Immunol. 2021 Jun 16;12:704773
pubmed: 34220867
Wien Klin Wochenschr. 2021 Apr;133(7-8):364-376
pubmed: 33523297
JAMA. 1980 Nov 21;244(20):2310-1
pubmed: 7431555
Clin Microbiol Infect. 2021 Aug;27(8):1173.e1-1173.e4
pubmed: 33957273
Kidney Int. 2021 Jun;99(6):1496-1498
pubmed: 33887318
Nephrol Dial Transplant. 2021 Aug 27;36(9):1756-1757
pubmed: 34450646
Transplantation. 2021 Jul 1;105(7):e72-e73
pubmed: 33741844
Transpl Infect Dis. 2009 Aug;11(4):290-7
pubmed: 19497072
Kidney Int. 2021 Jun;99(6):1275-1279
pubmed: 33931226
Medicina (Kaunas). 2021 Jul 19;57(7):
pubmed: 34357013
Kidney Int. 1997 Jul;52(1):212-6
pubmed: 9211365
Kidney Int. 2021 Sep;100(3):697-698
pubmed: 34270945
Kidney Int. 2021 Jun;99(6):1490-1492
pubmed: 33887317
Eur J Clin Microbiol Infect Dis. 1989 Oct;8(10):897-900
pubmed: 2512137
Nephrol Dial Transplant. 2021 Aug 27;36(9):1709-1716
pubmed: 33999200
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
Nephrol Dial Transplant. 2020 Nov 1;35(11):1973-1983
pubmed: 33151337
Clin J Am Soc Nephrol. 2021 Jul;16(7):1037-1042
pubmed: 33824157
Am J Transplant. 2021 Sep 22;:
pubmed: 34551181
Pol Arch Intern Med. 2021 Oct 27;131(10):
pubmed: 34632754
EBioMedicine. 2021 Aug;70:103524
pubmed: 34391096
Clin J Am Soc Nephrol. 2021 Aug;16(8):1258-1260
pubmed: 34031182
Clin J Am Soc Nephrol. 2021 Jul;16(7):1073-1082
pubmed: 34031181
Kidney Int. 2021 Jun;99(6):1492-1494
pubmed: 33887316
Nephrol Dial Transplant. 2002 Jun;17(6):1085-92
pubmed: 12032201
Nephrol Dial Transplant. 2021 Mar 09;:
pubmed: 33693778
N Engl J Med. 2021 Mar 17;384(15):1468-1470
pubmed: 33730471
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
Front Immunol. 2021 Jun 30;12:690698
pubmed: 34276681